drugset / Trial / NCT07058662
A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of BBM-D101 in the Treatment of Duchenne Muscular Dystrophy.
Phase 1/2
Recruiting
9 enrolled
Belief BioMed (Beijing) Co., Ltd
Belief BioMed Limited · collabShanghai Mianyi Biopharmaceutical Co., Ltd. · collabShanghai Xinzhi BioMed Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of the study is to evaluate the safety, tolerability, and efficacy of BBM-D101 to treat participants with Duchenne Muscular Dystrophy.
Timeline
- Start
- 2025-07-31
- Primary completion
- 2027-06-30
- Completion
- 2031-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BBM-D101 | Gene therapy (AAV / viral vector) | — | Intravenous |